www.standoutstocks.com: Stocks That Stand Out For Mar. 4th, 2010 Are March 3 ...
04.03.10
)
Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354
Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com
_________________________________________________
Thresher Industries, Inc. Expanding United States Sales Representation
HANFORD, Calif., March 3, 2010 -- Thresher Industries, Inc. (Pink Sheets: THRR) is pleased to announce that it is expanding its sales and marketing initiative to increase its clientele throughout the United States. Thresher is seeking sales representatives to promote its products and introduce its service to a variety of new clients across several vertical markets. The Company is launching its new initiative to stimulate long-term domestic growth.
Thresher Industries provides a full range of aluminum and metal composite alloy castings for a variety of industries including the military, aerospace, agricultural, automotive, sports and recreation. The Company currently markets these services through its Web site for industries in need of metal and aluminum castings. Customers can visit the Company's Web site to request quotes on the types of casting they require.
Source: Trading Markets (press release)
www.standoutstocks.com: Stocks That Stand Out For Mar. 4th, 2010 Are Mar 04 ...
04.03.10
)
Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354
Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com
_________________________________________________
Bonanza Oil and Gas Reports 50 Percent Increase in Production of the Jackson Well
HOUSTON, TX, Mar 04, 2010 -- Bonanza Oil and Gas, Inc., a Nevada Corporation (OTC Bulletin Board: BGOI) (the "Company"), an independent oil and gas company, is pleased to announce that the production level of the Jackson Well, in the past couple of months, has increased by approximately 50% after performing re-fracturing stimulation of the well.
The Jackson well is in the Apclark Field, Borden County, Texas, and is operated by Westerly Exploration, Inc. Apclark Field is 5 miles East of the Jo Mill Field and has produced over 54,000,000 barrels of oil.
The Company is continuing to evaluate other asset properties that may be purchased and/or merged into the Company. As of today, we have entered a Letter of Intent (LOI) for current production in Oklahoma, and are actively seeking additional producing opportunities. The transaction under LOI is subject to the drafting and negotiation of a final definitive agreement, performing due diligence as well as board approval of the Company. As such, there is no guarantee that the Company will be able to successfully close the above transaction.
Source: Trading Markets (press release)
Market Watch for Jazz Pharmaceuticals Inc. Issued by Beacon Equity
02.03.10
DALLAS, March 2, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotechnology company Jazz Pharmaceuticals Inc. (Nasdaq:JAZZ). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
The complete report is available at: http://www.beaconequity.com/i/JAZZ
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Jazz Pharmaceuticals Inc. engages in the development and commercialization of innovative products in the area of neurology and psychiatry in the United States. The Company's commercial products include Xyrem for the treatment of narcolepsy symptoms of daytime drowsiness and cataplexy; and Luvox CR for anxiety and obsessive compulsive disorders. The Company's product candidates presently in clinical trials include: JZP-6 (sodium oxybate) for the treatment of fibromyalgia, in Phase III clinical trials; JZP-7 (transdermal ropinirole gel) for the treatment of restless legs syndrome, in Phase II clinical trials; JZP-8 (intranasal clonazepam) for the treatment of recurrent acute repetitive seizures, in Phase II clinical trials; and JZP-4 (sodium channel antagonist) for the treatment of epilepsy and bipolar disorder, in Phase I clinical trials.
Source: CNNMoney.com (press release)